• Rattapol Pakchotanon Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
  • Wiyanoot Lomarat Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok
  • Pongthorn Narongroeknawin Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok
  • Sumapa Chaiamnuay Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok
  • Paijit Asavatanabodee Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok
Keywords: Systemic Lupus Erythematosus, Vitamin D level


Objective/background: Patients with systemic lupus erythematosus (SLE) have a high prevalence of vitamin D deficiency. We aimed to assess the efficacy and safety of ergocalciferol combined with standard care among patients with SLE.

Methods: A randomized, double-blinded, placebo-controlled study was conducted among patients with SLE (N=104). The patients were randomized to receive either a higher dosage of ergocalciferol (100,000 IU of ergocalciferol weekly for 4 weeks followed by 40,000 IU of ergocalciferol weekly for 20 weeks, group A (N=52) or placebo (group B, N=52). All patients received 800 units of cholecalciferol daily for 24 weeks. Concurrent medications were adjusted as clinically required. We compared demographics, serum 25-Hydroxy vitamin D (25(OH) D) levels, SLE disease activity index (SLEDAI-2K) and treatment variables between the two groups. The outcomes were measured at baseline, 12 and 24 weeks follow-up. These outcomes included serum 25(OH) D, SLEDAI-2K, SLE flare event defined by an increase of SLEDAI-2K between 2 visits, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), urine protein creatinine ratio (UPCR), health assessment questionnaire (HAQ), the change of dosage of immunosuppressive drugs and glucocorticoids (GCS) and ergocalciferol related toxicity. Subgroup analyses were also undertaken among patients with lupus nephritis. Continuous variables between the 2 groups were compared using student’s t-test whereas categorical groups were compared using the chi-square test.

Results: Of 104 patients, only 88 patients completed the study. Baseline characteristics between the 2 groups were similar. At 24 weeks, the mean ± standard difference (SD) of serum levels of 25(OH) D in group A was significantly higher than those in group B (41.2 ± 14.4 vs. 27.2 ± 10.1, p < 0.001). No difference was observed between groups A and B with respect to SLEDAI-2K, flare event, ESR, CRP and dosage of immunosuppressive drugs. However, at 12 and 24 weeks, the number of patients who could reduce GCS dosage in group A were significantly greater than group B (at 12 weeks, 39.6 vs. 17.6%, p = 0.008; at 24 weeks, 43.4 vs. 23.5%, p = 0.013). Subgroup analysis revealed no significant improvement of UPCR in group A compared with group B. Ergocalciferol related adverse reactions in both groups were similar. Serum calcium levels did not change within and between groups of treatment.

Conclusion: This study was inconclusive in demonstrating the efficacy of high dose ergocalciferol in controlling SLE disease activity. However, high dose ergocalciferol could be a safe adjunctive therapy that has a corticosteroid-sparing effect on patients with SLE.


Download data is not yet available.


Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 2010; 39: 255-69. DOI: https://doi.org/10.1016/j.ecl.2010.02.007

Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010; 95: 471-8. DOI: https://doi.org/10.1210/jc.2009-1773

Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010; 39: 365-79. DOI: https://doi.org/10.1016/j.ecl.2010.02.010

Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4: 404-12. DOI: https://doi.org/10.1038/ncprheum0855

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-96. DOI: https://doi.org/10.1016/j.coph.2010.04.001

Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634-47. DOI: https://doi.org/10.4049/jimmunol.179.3.1634

Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, Marinescu LM, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PloS One. 2010; 5: e9193. DOI: https://doi.org/10.1371/journal.pone.0009193

Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1569-74. DOI: https://doi.org/10.1136/ard.2010.148494

Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol 2012; 4: 146-51. DOI: https://doi.org/10.4161/derm.20443

Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 114-7. DOI: https://doi.org/10.1016/j.autrev.2005.05.009

Hamza RT, Awwad KS, Ali MK, Hamed AI. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Medical science monitor : Int Med J Ex Clin Res 2011; 17: CR711-8. DOI: https://doi.org/10.12659/MSM.882131

Cutillas-Marco E, Morales-Suarez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxy vitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010; 19: 810-4. DOI: https://doi.org/10.1177/0961203309360807

Sumethkul K, Boonyaratavej S, Kitumnuaypong T, Angthararuk S, Cheewasat P, Manadee N, et al. The predictive factors of low serum 25- hydroxy vitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. Rheumatol Int 2013; 33: 1461-7. DOI: https://doi.org/10.1007/s00296-012-2537-7

Chaiamnuay S, Chailurkit LO,Narongroeknawin P, Asavatanabodee P, Laohajaroensombat S, Chaiamnuay P. Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. J Clin Rheumatol 2013; 19: 121-5. DOI: https://doi.org/10.1097/RHU.0b013e318289bd16

Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 2012; 14: R221. DOI: https://doi.org/10.1186/ar4060

Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized place bocontrolled trial. Journal Rheumatol 2013; 40: 265-72. DOI: https://doi.org/10.3899/jrheum.111594

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725. DOI: https://doi.org/10.1002/art.1780400928

Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010; 9: 507-10. DOI: https://doi.org/10.1016/j.autrev.2010.02.011

Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2013; 25: 184-91. DOI: https://doi.org/10.1097/BOR.0b013e32835cfc16

Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 2001; 99: 82-93. DOI: https://doi.org/10.1006/clim.2000.4998

Bonakdar ZS, Jahanshahifar L, Jahanshahifar F, Gholamrezaei A. Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus 2011; 20: 1155-60. DOI: https://doi.org/10.1177/0961203311405703

Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2008; 67: 530-5. DOI: https://doi.org/10.1136/ard.2007.072736

Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum 2013; 65: 1865-71. DOI: https://doi.org/10.1002/art.37953

Toloza SM, Cole DE, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010; 19: 13-9. DOI: https://doi.org/10.1177/0961203309345775

How to Cite
Pakchotanon R, Lomarat W, Narongroeknawin P, Chaiamnuay S, Asavatanabodee P. RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL TO EVALUATE EFFICACY OF VITAMIN D SUPPLEMENTATION AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. J Southeast Asian Med Res [Internet]. 2020Jun.23 [cited 2022Jun.27];4(1):24-2. Available from: https://www.jseamed.org/index.php/jseamed/article/view/57
Original Articles